Celgene wins approval for drug key to Bristol buyout

Celgene wins approval for drug key to Bristol buyout

Source: 
Biopharma Dive
snippet: 

Celgene on Friday won U.S. approval for Inrebic, a treatment for myelofibrosis that is one of five drugs Bristol-Myers Squibb regarded as particularly valuable in its $74 billion deal to buy Celgene.